Stimulating a tumor-killing immune response

 

Founded in 2016, SapVax is advancing discoveries made by researchers from the University of Auckland in New Zealand.  Our academic founders have developed a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines.  The Sapvax team is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.

 

TECHNOLOGY

Read more about the development of our novel vaccines.

Learn More →

LeADERSHIP

Get to know our drug development experts.

Meet Our Team →